{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T14:31:54Z","timestamp":1746196314959},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T00:00:00Z","timestamp":1634947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T00:00:00Z","timestamp":1634947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Colorectal cancer (CRC) is the third most prevalent cancer worldwide and poses a serious challenge for clinicians. Previous studies have shown promising results in patients with Microsatellite Stable microsatellite-stable CRC refractory to chemotherapy upon treating with (Programmed Cell Death Protein 1) PD-1 inhibitor combined with regorafenib. Herein, we report a unique case of a patient for whom the conventional chemotherapy and radiotherapy were ineffective, but showed a prolonged stable disease with third-line treatment with regorafenib and PD-1 inhibitor, sintilimab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 64-year-old East Asian female patient was admitted to a regional cancer hospital presenting with abdominal unease due to increased stool frequency and bloody stool. Digital anal examination revealed adenocarcinoma, while genetic profiling of the tumor resections detected wild-type KRAS mutations in codon 12 and 13. Microsatellite instability (MSI) analysis for detecting germline mutations of (Mismatch-repair) MMR genes showed stable phenotype. In December 2016, Miles\u2019 resection for intestinal adhesion release and iliac vessel exploration in the rectum was performed (Tumor, Node, Metastasis [TNM]: T3N0M0; stage IIA). The adjuvant chemotherapeutic regimen consisted of a combination of capecitabine at 1.5\u00a0g (twice daily) and oxaliplatin therapy at 200\u00a0mg for three cycles from February 2016; followed by administering capecitabine tablets orally (1.5\u00a0g bid) for five cycles as post-operative palliative care. The patient tested positive for hepatic C virus, which was managed by oral antiviral agents. Following recurrence of rectal adenocarcinoma after 4\u00a0years and disease progression with a previous chemotherapeutic regimen, regorafenib was administered at 120\u00a0mg once daily combined with sintilimab 200\u00a0mg, and the patient's progress was monitored. A follow-up computerized tomography imaging in March 2020 showed disease progression, additionally presented nodule formation (TNM: T3NxM1b; stage IVB). According to Response Evaluation Criteria in Solid Tumors criteria (RECIST), the patient showed a complete response (CR) after treatment with regorafenib and sintilimab immunotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Data from this clinical case report support future exploration of combination treatment of the oral multi-kinase inhibitor regorafenib with PD-1 targeted monoclonal antibodies in patients with metastatic microsatellite-stable CRC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-021-01950-y","type":"journal-article","created":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T21:02:36Z","timestamp":1635022956000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature"],"prefix":"10.1186","volume":"21","author":[{"given":"Yong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingdi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiman","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanli","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,23]]},"reference":[{"key":"1950_CR1","unstructured":"Ferlay J, Laversanne M, Ervik M, Lam F, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F. Global cancer observatory: cancer tomorrow. International Agency for Research on Cancer, Lyon, France; 2020. https:\/\/gco.iarc.fr\/tomorrow. Accessed 15 Jan 2021."},{"key":"1950_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/gastro\/goz061","volume":"8","author":"N Huyghe","year":"2020","unstructured":"Huyghe N, Baldin P, Van den Eynde M. Immunotherapy with immune checkpoint inhibitors in colorectal cancer: What is the future beyond deficient mismatch-repair tumours? Gastroenterol Rep. 2020;8:11\u201324.","journal-title":"Gastroenterol Rep"},{"key":"1950_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.biopha.2016.12.064","volume":"87","author":"V Das","year":"2017","unstructured":"Das V, Kalita J, Pal M. Predictive and prognostic biomarkers in colorectal cancer: a systematic review of recent advances and challenges. Biomed Pharmacother Biomed Pharmacother. 2017;87:8\u201319.","journal-title":"Biomed Pharmacother Biomed Pharmacother"},{"key":"1950_CR4","doi-asserted-by":"publisher","first-page":"E2852","DOI":"10.3390\/jcm9092852","volume":"9","author":"G Sammarco","year":"2020","unstructured":"Sammarco G, Gallo G, Vescio G, Picciariello A, De Paola G, Trompetto M, et al. Mast cells, microRNAs and others: the role of translational research on colorectal cancer in the forthcoming era of precision medicine. J Clin Med. 2020;9:E2852.","journal-title":"J Clin Med"},{"key":"1950_CR5","first-page":"425","volume":"299","author":"AJ Schetter","year":"2008","unstructured":"Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299:425\u201336.","journal-title":"JAMA"},{"key":"1950_CR6","first-page":"127","volume":"90","author":"G Gallo","year":"2019","unstructured":"Gallo G, Sena G, Vescio G, Papandrea M, Sacco R, Trompetto M, et al. The prognostic value of KRAS and BRAF in stage I\u2013III colorectal cancer. A systematic review. Ann Ital Chir. 2019;90:127\u201337.","journal-title":"Ann Ital Chir"},{"key":"1950_CR7","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.3748\/wjg.v20.i22.6786","volume":"20","author":"G Binefa","year":"2014","unstructured":"Binefa G, Rodr\u00edguez-Moranta F, Teule \u00c0, Medina-Hayas M. Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol WJG. 2014;20:6786\u2013808. https:\/\/doi.org\/10.3748\/wjg.v20.i22.6786.","journal-title":"World J Gastroenterol WJG"},{"key":"1950_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4061\/2011\/219309","volume":"2011","author":"KM Sullivan","year":"2011","unstructured":"Sullivan KM, Kozuch PS. Impact of KRAS mutations on management of colorectal carcinoma. Pathol Res Int. 2011;2011:1\u201311. https:\/\/doi.org\/10.4061\/2011\/219309.","journal-title":"Pathol Res Int"},{"key":"1950_CR9","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.3390\/jcm9113520","volume":"9","author":"G Jung","year":"2020","unstructured":"Jung G, Ben\u00edtez-Ribas D, S\u00e1nchez A, Balaguer F. Current treatments of metastatic colorectal cancer with immune checkpoint inhibitors\u20142020 update. J Clin Med. 2020;9:3520.","journal-title":"J Clin Med"},{"key":"1950_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/9037217","volume":"2020","author":"M Kreidieh","year":"2020","unstructured":"Kreidieh M, Mukherji D, Temraz S, Shamseddine A. Expanding the scope of immunotherapy in colorectal cancer: current clinical approaches and future directions. BioMed Res Int. 2020;2020:1\u201324.","journal-title":"BioMed Res Int"},{"key":"1950_CR11","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509\u201320.","journal-title":"N Engl J Med"},{"key":"1950_CR12","doi-asserted-by":"publisher","first-page":"175628482091752","DOI":"10.1177\/1756284820917527","volume":"13","author":"G Golshani","year":"2020","unstructured":"Golshani G, Zhang Y. Advances in immunotherapy for colorectal cancer: a review. Ther Adv Gastroenterol. 2020;13:175628482091752.","journal-title":"Ther Adv Gastroenterol"},{"key":"1950_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41416-019-0599-y","volume":"121","author":"IH Sahin","year":"2019","unstructured":"Sahin IH, Akce M, Alese O, Shaib W, Lesinski GB, El-Rayes B, et al. Immune checkpoint inhibitors for the treatment of MSI-H\/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer. 2019;121:809\u201318. https:\/\/doi.org\/10.1038\/s41416-019-0599-y.","journal-title":"Br J Cancer"},{"key":"1950_CR14","doi-asserted-by":"publisher","first-page":"594558","DOI":"10.3389\/fonc.2020.594558","volume":"10","author":"L Zhang","year":"2020","unstructured":"Zhang L, Mai W, Jiang W, Geng Q. Sintilimab: a promising anti-tumor PD-1 antibody. Front Oncol. 2020;10:594558.","journal-title":"Front Oncol"},{"key":"1950_CR15","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0161","author":"C Wang","year":"2020","unstructured":"Wang C, Chevalier D, Saluja J, Sandhu J, Lau C, Fakih M. Regorafenib and nivolumab or pembrolizumab combination and circulating tumor DNA response assessment in refractory microsatellite stable colorectal cancer. Oncologist. 2020. https:\/\/doi.org\/10.1634\/theoncologist.2020-0161.","journal-title":"Oncologist"},{"key":"1950_CR16","doi-asserted-by":"publisher","first-page":"e000404","DOI":"10.1136\/jitc-2019-000404","volume":"8","author":"A Puccini","year":"2020","unstructured":"Puccini A, Battaglin F, Iaia ML, Lenz H-J, Salem ME. Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. J Immunother Cancer. 2020;8:e000404.","journal-title":"J Immunother Cancer"},{"key":"1950_CR17","doi-asserted-by":"publisher","first-page":"101912","DOI":"10.1016\/j.ctrv.2019.101912","volume":"81","author":"H Arai","year":"2019","unstructured":"Arai H, Battaglin F, Wang J, Lo JH, Soni S, Zhang W, et al. Molecular insight of regorafenib treatment for colorectal cancer. Cancer Treat Rev. 2019;81:101912.","journal-title":"Cancer Treat Rev"},{"key":"1950_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16:361\u201375.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1950_CR19","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1200\/JCO.19.03296","volume":"38","author":"S Fukuoka","year":"2020","unstructured":"Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol. 2020;38:2053\u201361. https:\/\/doi.org\/10.1200\/JCO.19.03296.","journal-title":"J Clin Oncol"},{"key":"1950_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.annonc.2020.04.073","volume":"31","author":"R Kim","year":"2020","unstructured":"Kim R, Imanirad I, Carballido E, Strosberg J, Kim Y, Kim D. O-20 Phase I\/IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Ann Oncol. 2020;31:239. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.073.","journal-title":"Ann Oncol"},{"key":"1950_CR21","doi-asserted-by":"publisher","first-page":"594125","DOI":"10.3389\/fonc.2020.594125","volume":"10","author":"J Li","year":"2020","unstructured":"Li J, Cong L, Liu J, Peng L, Wang J, Feng A, et al. The efficacy and safety of regorafenib in combination with anti-PD-1 antibody in refractory microsatellite stable metastatic colorectal cancer: a retrospective study. Front Oncol. 2020;10:594125. https:\/\/doi.org\/10.3389\/fonc.2020.594125.","journal-title":"Front Oncol"},{"key":"1950_CR22","doi-asserted-by":"publisher","first-page":"12477","DOI":"10.2147\/OTT.S284092","volume":"13","author":"E Zhang","year":"2020","unstructured":"Zhang E, Zhang Z, Li J, Huang Z. Complete response to the sequential treatment with regorafenib followed by PD-1 inhibitor in a sorafenib-refractory hepatocellular carcinoma patient. OncoTargets Ther. 2020;13:12477\u201387. https:\/\/doi.org\/10.2147\/OTT.S284092.","journal-title":"OncoTargets Ther"},{"key":"1950_CR23","doi-asserted-by":"publisher","DOI":"10.20517\/2394-4722.2021.61","author":"M Cefal\u00ec","year":"2021","unstructured":"Cefal\u00ec M, Epistolio S, Palmarocchi MC, Frattini M, De Dosso S. Research progress on KRAS mutations in colorectal cancer. J Cancer Metastasis Treat. 2021. https:\/\/doi.org\/10.20517\/2394-4722.2021.61.","journal-title":"J Cancer Metastasis Treat"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01950-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-01950-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01950-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T21:03:02Z","timestamp":1635022982000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-01950-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,23]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1950"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-01950-y","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,23]]},"assertion":[{"value":"3 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Medical Ethics Committee of Henan cancer hospital (approval number: 2019029). Written informed consent was obtained from the patient for participating in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"399"}}